edoc

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS)

Preiningerova, J. L. and Baumhackl, U. and Csepany, T. and Czaplinski, A. and Deisenhammer, F. and Derfuss, T. and Fabjan, T. H. and Fazekas, F. and Fuchs, S. and Havrdova, E. and Ledinek, A. H. and Illes, Z. and Jazbec, S. S. and Klimova, E. and Komoly, S. and Kurca, E. and Linnebank, M. and Lisy, L. and Mares, J. and Prochazkova, L. and Csilla, R. and Szilasiova, J. and Stourac, P. and Talab, R. and Turcani, P. and Vachova, M. and Vecsei, L. and Vodusek, D. and Zapletalova, O. and Berger, T.. (2013) Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). CNS neuroscience & therapeutics, Vol. 19, H. 5. pp. 302-306.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6338643

Downloads: Statistics Overview

Abstract

Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Clinical Neuroimmunology (Derfuss/Lindberg)
UniBasel Contributors:Derfuss, Tobias Johannes
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Wiley-Blackwell
ISSN:1755-5930
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:10 Apr 2015 09:13
Deposited On:10 Apr 2015 09:13

Repository Staff Only: item control page